MedTrace Logo

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

NCT03241810 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-09-02

Study results available
· View outcomes & findings →

Summary

This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.

Conditions

Interventions

DRUG

Seribantumab

Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling

DRUG

Fulvestrant

Fulvestrant is an estrogen receptor antagonist with no agonist effects

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Elevation Oncology

    lead INDUSTRY

Principal Investigators

  • Marc Pipas, MD · Merrimack Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2018-11-30
Completion
2018-11-30
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241810 on ClinicalTrials.gov